Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab
By Denny Jacob
Scholar Rock Holding said the Food and Drug Administration cleared its investigational new drug application for its Phase 2 trial of apitegromab to treat obesity in patients taking a GLP-1 receptor agonist.
The late-stage biopharmaceutical company said trial initiation is on track for mid-2024 and data from the trial is expected in mid-2025.
In parallel, Scholar Rock is developing SRK-439 also to treat obesity. It plans to file an investigational new drug application for SRK-439 in 2025.
"The FDA's acceptance of our IND application to study apitegromab in obesity allows us to assess the effect of our highly selective myostatin inhibitor on preserving lean muscle mass, and safety and tolerability of our approach when combined with a GLP-1 RA," said Chief Executive Jay Backstrom.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 23, 2024 08:47 ET (13:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors